Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright

Inozyme Pharma, Inc. (NASDAQ:INZY) – Equities researchers at HC Wainwright dropped their Q1 2025 earnings per share estimates for Inozyme Pharma in a report released on Tuesday, March 11th. HC Wainwright analyst E. White now forecasts that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.43). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.40) EPS and FY2026 earnings at ($1.11) EPS.

A number of other research analysts have also issued reports on INZY. Wedbush reiterated an “outperform” rating and issued a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a report on Monday. Needham & Company LLC decreased their price target on Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday. Wells Fargo & Company decreased their price target on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Piper Sandler decreased their price target on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Raymond James decreased their price target on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Inozyme Pharma has a consensus rating of “Buy” and a consensus target price of $14.56.

Inozyme Pharma Trading Down 7.4 %

NASDAQ:INZY opened at $1.00 on Thursday. The firm has a market cap of $64.22 million, a PE ratio of -0.64 and a beta of 1.32. The stock has a fifty day moving average price of $1.48 and a 200 day moving average price of $3.26. Inozyme Pharma has a 12-month low of $0.98 and a 12-month high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Institutional Trading of Inozyme Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in INZY. Harvest Investment Services LLC acquired a new stake in shares of Inozyme Pharma during the fourth quarter worth about $31,000. Graham Capital Management L.P. acquired a new position in Inozyme Pharma in the 4th quarter valued at about $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Inozyme Pharma in the 4th quarter valued at about $38,000. D. E. Shaw & Co. Inc. acquired a new position in Inozyme Pharma in the 4th quarter valued at about $49,000. Finally, ProShare Advisors LLC acquired a new position in Inozyme Pharma in the 4th quarter valued at about $49,000. Institutional investors and hedge funds own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.